1) Strategy & Leadership
- Joaquin Duato, CEO, emphasized 2026 as a year of accelerated growth, reporting strong Q2 results and raised guidance.
- The company has 28 products generating over $1 billion in annual sales, showcasing a robust portfolio and pipeline.
- Johnson & Johnson aims to be the number one oncology company by 2030, with projected sales exceeding $50 billion.

2) Financial & Segment Results
- Q2 2026 worldwide sales reached $25.3 billion, a 5.6% increase YoY, with operational growth of 6.8% in Innovative Medicine.
- Net earnings were $5.5 billion, with diluted EPS of $2.27. Adjusted EPS increased to $2.90, up 4.7% YoY.
- Key growth drivers included:
- Oncology: DARZALEX grew 17.6%, CARVYKTI 47.7%, and TECVAYLI 56.1%.
- Immunology: TREMFYA surged 71%, while STELARA declined 55.7% due to biosimilar competition.
- MedTech: Sales of $8.9 billion grew 3.6%, with notable performance in cardiovascular and surgery segments.

3) Problems / Headwinds
- STELARA's decline impacted overall growth, contributing to a 460 basis point headwind.
- Abiomed's growth slowed due to increased physician selectivity and a recent neutral clinical trial affecting procedure volumes.
- Competitive pressures in MedTech, particularly in electrophysiology, contributed to lower-than-expected growth.

4) Operational or Product Plans
- New product launches, including ICOTYDE and INLEXZO, are expected to drive future growth, with ICOTYDE showing strong early uptake.
- The company plans to acquire Firefly Bio to enhance its oncology pipeline.
- Upcoming catalysts include FDA approvals for several products and continued expansion in the robotics segment with OTTAVA and MONARCH.

5) Guidance & Outlook / Investor Angle
- Full-year operational sales growth guidance increased to 6.5%-7.1%, with a projected midpoint of $100.6 billion.
- Adjusted operational EPS guidance raised to $11.50-$11.65, reflecting a 7.3% YoY growth.
- The company remains committed to returning capital to shareholders primarily through dividends, while maintaining a strong cash position of approximately $21 billion.

Bottom line: Johnson & Johnson's strong Q2 performance and raised guidance reflect a solid growth trajectory, driven by a diverse portfolio and innovative product launches, positioning the company favorably for long-term shareholder value.